



INFECTIOUS DISEASES SOCIETY OF AMERICA EMERGING INFECTIONS NETWORK QUERY:

Antifungal Therapeutic Drug Monitoring

Therapeutic drug monitoring (TDM) is recommended for hospitalized patients receiving certain antifungals for treatment or prophylaxis. Antifungal TDM may be under-used, potentially leading to subtherapeutic drug levels and preventable drug toxicity.

The purpose of this survey is to help us understand how commonly therapeutic drug monitoring for certain antifungals is performed and potential barriers to performing these tests.

Note: *Fluconazole levels are not routinely recommended; however, we are aware that some practitioners order these levels for specific infections, e.g. coccidioidomycosis.

EMERGING INFECTIONS NETWORK QUERY

Antifungal Therapeutic Drug Monitoring

Name: _____

___ Do not routinely care for patients with invasive fungal infections -- *please STOP HERE*

Antifungals for TREATMENT of Invasive Fungal Infections

1. In the past 12 months, about how many patients have you treated for an invasive fungal infection using each of the antifungal medications below?

Itraconazole	___ Up to 5	___ 6-10	___ 11-20	___ 21-30	___ >30
Posaconazole	___ Up to 5	___ 6-10	___ 11-20	___ 21-30	___ >50
Voriconazole	___ Up to 5	___ 6-10	___ 11-20	___ 21-30	___ >50
Isavuconazole	___ Up to 5	___ 6-10	___ 11-20	___ 21-30	___ >50
Fluconazole	___ Up to 5	___ 6-10	___ 11-20	___ 21-30	___ >50

2. In the past 12 months, for what percent of these patients (in #1 above) did you request therapeutic drug monitoring?

Itraconazole	___ None	___ 1-20%	___ 21-50%	___ 51-75%	___ >75%
Posaconazole	___ None	___ 1-20%	___ 21-50%	___ 51-75%	___ >75%
Voriconazole	___ None	___ 1-20%	___ 21-50%	___ 51-75%	___ >75%
Isavuconazole	___ None	___ 1-20%	___ 21-50%	___ 51-75%	___ >75%
Fluconazole	___ None	___ 1-20%	___ 21-50%	___ 51-75%	___ >75%

Antifungals for PROPHYLAXIS of Invasive Fungal Infections

___ No, do not routinely care for patients on antifungal prophylaxis - *Skip Q3 and Q4*

3. In the past 12 months, have you cared for any patients receiving the following antifungals for prophylaxis?

Itraconazole	___ Up to 5	___ 6-10	___ 11-20	___ 21-30	___ >30
Posaconazole	___ Up to 5	___ 6-10	___ 11-20	___ 21-30	___ >50
Voriconazole	___ Up to 5	___ 6-10	___ 11-20	___ 21-30	___ >50
Isavuconazole	___ Up to 5	___ 6-10	___ 11-20	___ 21-30	___ >50
Fluconazole	___ Up to 5	___ 6-10	___ 11-20	___ 21-30	___ >50

4. In the past 12 months, for what percent of these patients (in #3 above) did you request therapeutic drug monitoring?

Itraconazole	___ None	___ 1-20%	___ 21-50%	___ 51-75%	___ >75%
Posaconazole	___ None	___ 1-20%	___ 21-50%	___ 51-75%	___ >75%
Voriconazole	___ None	___ 1-20%	___ 21-50%	___ 51-75%	___ >75%
Isavuconazole	___ None	___ 1-20%	___ 21-50%	___ 51-75%	___ >75%
Fluconazole	___ None	___ 1-20%	___ 21-50%	___ 51-75%	___ >75%

5. Do you find the hydroxy-itraconazole level helpful in a patient's clinical care?

___ N/A, do not use

___ Never ___ Rarely ___ Sometimes ___ Often ___ Always

6. Which barriers, if any, concern you or prevent you from performing therapeutic drug monitoring for antifungals? *[Select any that apply]*

- ☐ Long turnaround times for send-out tests
- ☐ Difficult to coordinate logistics of testing (e.g. through home health or outside labs)
- ☐ Cost
- ☐ Challenges with insurance coverage, including pre-authorization
- ☐ Uncertainty around therapeutic drug monitoring recommendations (lack of U.S. guidelines)
- ☐ Difficulty of interpreting results (i.e. not sure what target level should be)
- ☐ Unsure of benefit of therapeutic drug monitoring
- ☐ Other, *specify*:
- ☐ None

7. What additional thoughts or comments would you like to share about your use of therapeutic drug monitoring for antifungals?

Thank you for completing this survey!